Saéz-López et al., using SHBG-C57BL transgenic mice compared with wild control and ksJ-db/db mice, showed that SHBG could play a role in arresting the progression of NAFLD by downregulating key lipogenic enzymes in the liver, such as ACC and PPARγ, thus reducing lipogenesis [77,78]. The gene discussed is SHBG; the disease is metabolic dysfunction-associated steatotic liver disease.